Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthew A Gubens

Showing results (11-20 of 59) with videos related to

Pageof 6
Sort By:
Lung Cancer (Amsterdam, Netherlands)|May 27, 2015
A phase II study of saracatinib (AZD0530), a Src inhibitor, administered orally daily to patients with advanced thymic malignanciesMatthew A Gubens, Matthew Burns, Susan M Perkins, et al.
Endocrine-Related Cancer|October 26, 2023
Survival outcomes for lung neuroendocrine tumors in California differ by sociodemographic factorsClaire K Mulvey, Alan Paciorek, Farhana Moon, et al.
Clinical Lung Cancer|September 21, 2021
Molecular Risk Stratification is Independent of EGFR Mutation Status in Identifying Early-Stage Non-Squamous Non-Small Cell Lung Cancer Patients at Risk for Recurrence and Likely to Benefit From Adjuvant ChemotherapyGavitt A Woodard, Johannes R Kratz, Greg Haro, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 18, 2014
A phase I dose escalation and expansion study of the anticancer stem cell agent demcizumab (anti-DLL4) in patients with previously treated solid tumorsDavid C Smith, Peter D Eisenberg, Georgy Manikhas, et al.
JTO Clinical and Research Reports|December 22, 2022
Phase 1 Study of Ceritinib Combined With Trametinib in Patients With Advanced ALK- or ROS1-Positive NSCLCMatthew S Lara, Matthew A Gubens, Bianca Bacaltos, et al.
Journal of Thoracic Disease|March 31, 2018
A pooled analysis of advanced nonsquamous non-small cell lung cancer patients with stable treated brain metastases in two phase II trials receiving bevacizumab and pemetrexed as second-line therapyMatthew A Gubens, Jody C Chuang, Wallace Akerley, et al.
Clinical Lung Cancer|September 27, 2014
Prognostic molecular assay might improve identification of patients at risk for recurrence in early-stage non-small-cell lung cancerGavitt A Woodard, Matthew A Gubens, Thierry M Jahan, et al.
Scientific Reports|March 14, 2017
Novel computational method for predicting polytherapy switching strategies to overcome tumor heterogeneity and evolutionVanessa D Jonsson, Collin M Blakely, Luping Lin, et al.
Clinical Lung Cancer|June 25, 2017
Adjuvant Chemotherapy Guided by Molecular Profiling and Improved Outcomes in Early Stage, Non-Small-Cell Lung CancerGavitt A Woodard, Sue X Wang, Johannes R Kratz, et al.
Lung Cancer (Amsterdam, Netherlands)|September 27, 2019
Phase II trial of single agent amrubicin in patients with previously treated advanced thymic malignanciesJessica A Hellyer, Matthew A Gubens, Kristen M Cunanan, et al.
Pageof 6

Showing results (11-20 of 59) with videos related to

Sort By:
Pageof 6
Lung Cancer (Amsterdam, Netherlands)|May 27, 2015
A phase II study of saracatinib (AZD0530), a Src inhibitor, administered orally daily to patients with advanced thymic malignanciesMatthew A Gubens, Matthew Burns, Susan M Perkins, et al.
Endocrine-Related Cancer|October 26, 2023
Survival outcomes for lung neuroendocrine tumors in California differ by sociodemographic factorsClaire K Mulvey, Alan Paciorek, Farhana Moon, et al.
Clinical Lung Cancer|September 21, 2021
Molecular Risk Stratification is Independent of EGFR Mutation Status in Identifying Early-Stage Non-Squamous Non-Small Cell Lung Cancer Patients at Risk for Recurrence and Likely to Benefit From Adjuvant ChemotherapyGavitt A Woodard, Johannes R Kratz, Greg Haro, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 18, 2014
A phase I dose escalation and expansion study of the anticancer stem cell agent demcizumab (anti-DLL4) in patients with previously treated solid tumorsDavid C Smith, Peter D Eisenberg, Georgy Manikhas, et al.
JTO Clinical and Research Reports|December 22, 2022
Phase 1 Study of Ceritinib Combined With Trametinib in Patients With Advanced ALK- or ROS1-Positive NSCLCMatthew S Lara, Matthew A Gubens, Bianca Bacaltos, et al.
Journal of Thoracic Disease|March 31, 2018
A pooled analysis of advanced nonsquamous non-small cell lung cancer patients with stable treated brain metastases in two phase II trials receiving bevacizumab and pemetrexed as second-line therapyMatthew A Gubens, Jody C Chuang, Wallace Akerley, et al.
Clinical Lung Cancer|September 27, 2014
Prognostic molecular assay might improve identification of patients at risk for recurrence in early-stage non-small-cell lung cancerGavitt A Woodard, Matthew A Gubens, Thierry M Jahan, et al.
Scientific Reports|March 14, 2017
Novel computational method for predicting polytherapy switching strategies to overcome tumor heterogeneity and evolutionVanessa D Jonsson, Collin M Blakely, Luping Lin, et al.
Clinical Lung Cancer|June 25, 2017
Adjuvant Chemotherapy Guided by Molecular Profiling and Improved Outcomes in Early Stage, Non-Small-Cell Lung CancerGavitt A Woodard, Sue X Wang, Johannes R Kratz, et al.
Lung Cancer (Amsterdam, Netherlands)|September 27, 2019
Phase II trial of single agent amrubicin in patients with previously treated advanced thymic malignanciesJessica A Hellyer, Matthew A Gubens, Kristen M Cunanan, et al.
Pageof 6